Business
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
FDA laboratory testing confirms SAB-185 neutralizes Omicronand other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"FDA laboratory testing confirms SAB-185 neutralizes Omicronand other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue to show broad neutralization to viral variants SAB-185 currently being evaluated in NIH-sponsored Phase 3 COVID trial SIOUX FALLS, S.D., Dec. 16, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced data demonstrating that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The data were generated by scientists at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER). “These in vitro data demonstrate that SAB-185 retains neutralization activity against the Omicron variant as has been consistently shown with previous SARS-CoV-2 variants of concern,” said Eddie J. Sullivan, PhD, Co-founder, President and CEO of SAB Biotherapeutics. “These encouraging data come at a critical time as COVID continues to assert its resilience in the human population around the globe. It also provides further evidence of the potential therapeutic importance of our polyclonal antibody approach to a highly mutating virus such as SARS-CoV-2.” In the study, FDA researchers evaluated SAB-185 using a lentiviral-based pseudovirus assay conducted in a BSL2 environment that incorporates a stable 293T cell line expressing human angiotensin converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). The results indicate that SAB-185 retains a potent ability to neutralize recombinant S protein lentiviral pseudovirus that mimics the SARS-CoV-2 Omicron (B.1.1.529) variant. Although SAB-185 retained potent neutralization of the Omicron variant, it did show a mild-moderate reduction in potency compared to the wild type. Additional analyses are ongoing, and the full data set is being prepared for bioRxiv, the online life sciences archive for COVID-19 SARS-CoV-2 preprints. “As a targeted, high potency fully-human polyclonal antibody therapeutic candidate, SAB-185 is ...